Skip to main content

Treatment as Prevention of HIV Transmission


July 27, 2012 (Washington, DC) — "The paradigm for use of antiretroviral therapy has shifted; treatment and prevention have converged," a panel from the International Association of Physicians in AIDS Care (IAPAC) announced here at AIDS 2012: XIX International AIDS Conference.
The foundation of the approach requires treatment as soon as HIV-positivity is established and the use of preexposure prophylaxis, said José M. Zuniga, PhD, MPH, a member of the IAPAC from Washington, DC.
"Successful treatment as prevention will require higher levels of HIV testing, enhanced linkage to and retention in care, access to quality treatment, adherence support, and new ways to monitor coverage and treatment," reports the IAPAC panel in its consensus statement.
Julio Montaner, MD, director of the British Columbia Center for Excellence in HIV/AIDS, chair in AIDS research and head of division of AIDS at the University of British Columbia in Vancouver, Canada, and past-president of the International AIDS Society, told meeting attendees that this should put to rest any discussion: "Treating the individual helps them but also helps reduce transmission of the virus.... Early treatment reduces morbidity, mortality, and transmission."
"It is no longer a matter of whether we want to treat or if we can; now we know we have to," Dr. Montaner explained.
"I think we can curb the AIDS epidemic," copanelist Kenneth Brayer, MD, professor of medicine and of epidemiology at Brown University in Providence, Rhode Island, told Medscape Medical News. "There are compelling data that these efforts work."
"We need to decriminalize treatment," Dr. Montaner added. Efforts at HIV detection and treatment directed at prison populations and sex workers are well underway in Canada, he said. Convincing politicians that early access to affordable treatment decreases morbidity and mortality and reduces HIV transmission is something that needs to be tackled, he noted.
"Our challenge is how to convey hope...that ending AIDS is more than a cliché," Dr. Zuniga said.
The speakers have disclosed no relevant financial relationships.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...

Patients With IBS More Likely to Keep Taking Rifaximin

March 29, 2012 — Patients who take the antibiotic rifaximin for irritable bowel syndrome (IBS) with diarrhea are far less likely to stop using the drug because of adverse effects than patients taking 2 other common IBS treatments, according to a study by Eric Shah, MBA, from the School of Medicine at the Texas Tech University Health Sciences Center in Lubbock. The study was published online March 26 and in the April print issue of the American Journal of Medicine . A research team led by Mark Pimentel, MD, from the GI Motility Program at the Cedars-Sinai Medical Center in Los Angeles, California, reviewed 26 clinical trials of drugs for IBS with diarrhea and for IBS with constipation. In forms of IBS with diarrhea, the review found that patients experienced fewer adverse effects from the antibiotic rifaximin than patients who used tricyclic antidepressants or stool-slowing alosetron. For every 2.3 and 2.6 patients who benefited from antidepressants or alosetron, respectively, 1 had...